Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A340149-25mg | 25mg | In stock | $78.90 | |
A340149-50mg | 50mg | In stock | $129.90 | |
A340149-100mg | 100mg | In stock | $205.90 | |
A340149-250mg | 250mg | In stock | $463.90 | |
A340149-1g | 1g | In stock | $1,668.90 |
a potent inhibitor of cytokines IL-12 and IL-23 production which are potential regulators of certain autoimmune and inflammatory diseases
Synonyms | GFW2K84S4L | Apilimod [INN] | HY-14644 | AKOS015909602 | N-[6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-N'-[1-m-tolyl-meth-(E)-ylidene]-hydrazine | BA177430 | Apilimod | N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Apilimod (STA-5326) is a potent, orally active and selective inhibitor of the cytokines IL-12 and IL-23. Apilimod selectively suppresses synthesis of IL-12 and IL-23 by inhibition of phosphotransferase activity of TLR-4 regulator lipid kinase PIKfyve (pho |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor |
Product Description | Apilimod is a potent inhibitor of the cytokines IL-12 and IL-23 production. IL-12 and IL-23 are potential regulators of certain autoimmune and inflammatory diseases.|The following water-soluble salt forms are also available:|Apilimod Hydrochloride |Apilimod mesylate |
ALogP | 3.8 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine |
---|---|
INCHI | InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+ |
InChi Key | HSKAZIJJKRAJAV-KOEQRZSOSA-N |
Canonical SMILES | CC1=CC(=CC=C1)C=NNC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4 |
Isomeric SMILES | CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4 |
PubChem CID | 10173277 |
Molecular Weight | 418.49 |
CAS Registry No. | 541550-19-0 |
---|---|
PubChem CID | 10173277 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2318896 | Certificate of Analysis | Jan 16, 2023 | A340149 |
B2318956 | Certificate of Analysis | Jan 16, 2023 | A340149 |
B2318957 | Certificate of Analysis | Jan 16, 2023 | A340149 |
B2318959 | Certificate of Analysis | Jan 16, 2023 | A340149 |
B2318961 | Certificate of Analysis | Jan 16, 2023 | A340149 |
Solubility | insoluble in H2O; ≥17.9 mg/mL in DMSO; ≥6.86 mg/mL in EtOH with ultrasonic |
---|---|
Melt Point(°C) | 70-80° C |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H302:Harmful if swallowed |
Precautionary Statements | P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help. |
1. Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L, Wu Y, Qin J, Balasubramanyam V et al.. (2007) Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.. Blood, 109 (3): (1156-64). [PMID:17053051] [10.1021/op500134e] |
2. Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, Tatsuta N, Jacobson E, Barsoum J, Krueger JG. (2012) Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.. PLoS ONE, 7 (4): (e35069). [PMID:22493730] [10.1021/op500134e] |
3. Cai X, Xu Y, Cheung AK, Tomlinson RC, Alcázar-Román A, Murphy L, Billich A, Zhang B, Feng Y, Klumpp M et al.. (2013) PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.. Chem Biol, 20 (7): (912-21). [PMID:23890009] [10.1021/op500134e] |
4. Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T et al.. (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.. Blood, 129 (13): (1768-1778). [PMID:28104689] [10.1021/op500134e] |
5. Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS et al.. (2017) The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.. PLoS Negl Trop Dis, 11 (4): (e0005540). [PMID:28403145] [10.1021/op500134e] |
6. Baranov MV, Bianchi F, van den Bogaart G. (2020) The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.. Cells, 10 (1): (30). [PMID:33375410] [10.1021/op500134e] |
7. Qiu S, Leung A, Bo Y, Kozak RA, Anand SP, Warkentin C, Salambanga FDR, Cui J, Kobinger G, Kobasa D et al.. (2018) Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry.. Virology, 513 (13): (17-28). [PMID:29031163] [10.1021/op500134e] |
8. Logue J, Chakraborty AR, Johnson R, Goyal G, Rodas M, Taylor LJ, Baracco L, McGrath ME, Haupt R, Furlong BA et al.. (2022) PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.. Commun Biol, 5 (1): (808). [PMID:35962188] [10.1021/op500134e] |
9. Baranov MV, Bianchi F, Schirmacher A, van Aart MAC, Maassen S, Muntjewerff EM, Dingjan I, Ter Beest M, Verdoes M, Keyser SGL et al.. (2019) The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation.. iScience, 11 (13): (160-177). [PMID:30612035] [10.1021/op500134e] |
10. Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, Lysvand H, Løseth K, Landsem VM, Malmring JF et al.. (2020) Potential Antiviral Options against SARS-CoV-2 Infection.. Viruses, 12 (6): (1755-70). [PMID:32545799] [10.1021/op500134e] |